XDx, Inc. Announces that Medi-Cal Agrees to Cover AlloMap® for Monitoring Heart Transplant Recipients

Published: Mar 19, 2013

BRISBANE, Calif.--(BUSINESS WIRE)--XDx, Inc., a molecular diagnostics company that discovers, develops and commercializes high value, non-invasive tests to monitor immune status in transplant recipients and autoimmune diseases, announced today that Medi-Cal, the California State Medicaid Program and one of the largest insurers in the United States, is now covering AlloMap® for its beneficiaries. Medi-Cal added AlloMap as a new, covered benefit, considering the test medically necessary for the surveillance of heart transplant recipients for organ rejection. AlloMap now is covered by over 200 insurers in the United States, and more than 80% of tests performed over the past year have been reimbursed.

Back to news